It was remarkable that the inhibition of complement signalling via the subcutaneous administration of C5aR antagonist in those mice significantly diminished tumor growth to a similar degree as the effect caused by the anti-cancer drug paclitaxel [20]. Here, C5AR1 is linked to neoplasm.